DVA vs HNGE: How DaVita and Hinge Health Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DVA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DVA and HNGE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DVA and HNGE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

DaVita Inc. (NYSE: DVA) is a Denver, Colorado based kidney care company and the largest provider of dialysis services in the United States. As of June 30, 2026 it treated approximately 298,500 patients across 3,266 outpatient dialysis centers, of which 2,671 are in the US and 595 are spread across 14 other countries. The core business is straightforward and repetitive: patients with end stage renal disease come in roughly three times a week for a treatment that keeps them alive, and DaVita bills a payer for each treatment. Around that base the company runs two smaller segments, an international dialysis business and Integrated Kidney Care (IKC), a value-based care arm that took risk on roughly 62,600 patients and about $5.4 billion of annualized medical spend as of early 2026.

Full DVA guide

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DVA drivers: The buyback is the growth engine; Volume trends turned less bad.
• HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Payer mix is the dominant risk and it is currently moving the wrong way: the expiration of enhanced ACA premium subsidies is pushing patients out of commercial plans and into government coverage, which management sized as roughly a $40 million headwind in 2026 with a larger one expected in 2027. For HNGE, digital health categories are competitive with various platforms targeting MSK and other condition areas.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DVA if you believe its drivers more; HNGE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DVA and HNGE guides.

DVA. DVA trades at a visible discount to the broader healthcare sector, roughly 16x trailing and 12x forward earnings versus a healthcare industry average in the mid 20s, and that gap is the argument in both directions. Bulls read it as a cheap, defensive, non-discretionary cash machine with a shrinking share count. Bears read it as an appropriate multiple for a business with sub-1% volume growth, negative revenue-per-treatment guidance for the second half of 2026, roughly 3.4x leverage, and a profit pool concentrated in a thin commercially insured minority of patients that is actively eroding. The stock fell sharply in early August 2026 after Q2 results beat on both revenue and adjusted EPS but management reaffirmed rather than raised full-year guidance at a midpoint below consensus, which is a reminder that the multiple is doing very little cushioning work when the mix narrative turns.

HNGE. Hinge Health's valuation reflects the digital health growth premium, the demonstrated category leadership in MSK, and the path-to-profitability story. As a recent IPO, valuation is sensitive to broader digital health sector sentiment and to quarterly progression toward profitability.

Headline figures (approximate, August 2026): DVA shows revenue (ttm) ~$14.0 billion (up ~6.4% year over year), revenue (q2 2026) ~$3.55 billion, with adjusted operating income of ~$579 million, net income (ttm) ~$847 million, with trailing EPS of ~$12.11, fy 2026 adjusted eps guidance ~$14.10 to ~$15.20 (midpoint ~$14.65), reaffirmed not raised; HNGE shows revenue (ttm) ~$400 million (estimated, post-IPO disclosure), operating margin Approaching breakeven; varies by quarter, net income (ttm) Modest GAAP loss; non-GAAP near breakeven, eps (ttm) Near zero.

DVA and HNGE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DVA and HNGE exposure against your real portfolio. It is not an investment adviser.